Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Argent Biopharma ( (AU:RGT) ) is now available.
Argent BioPharma has announced the issuance of 3,333,333 fully paid ordinary shares, which are exempt from certain disclosure requirements under the Corporations Act 2001. This move is in compliance with relevant provisions, ensuring transparency and maintaining investor confidence. The issuance supports the company’s ongoing efforts to advance its clinical programs and strengthen its market position in addressing unmet medical needs.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company focused on developing nano-engineered medicines that address the balance between the nervous and immune systems. The company’s lead candidates, CannEpil® and CimetrA®, are designed to treat drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. Argent BioPharma leverages proprietary delivery platforms to enhance drug penetration across critical barriers, aiming to address urgent unmet needs in central nervous system and systemic inflammation.
Average Trading Volume: 88,091
Technical Sentiment Signal: Sell
Current Market Cap: A$8.03M
See more data about RGT stock on TipRanks’ Stock Analysis page.